<DOC>
	<DOC>NCT02817217</DOC>
	<brief_summary>The purpose of the study is to investigate the potential PK interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy male volunteers.</brief_summary>
	<brief_title>The DDI Study of SP2086 and Valsartan</brief_title>
	<detailed_description />
	<mesh_term>Valsartan</mesh_term>
	<criteria>Healthy volunteers with a body mass index (BMI, a measure of a person's weight in relation to height) between 19 and 26 kg/m2. History of diabetes History of heart failure or renal insufficiency Urinary tract infections, or vulvovaginal mycotic infections History of or current clinically significant medical illness as determined by the Investigator History of clinically significant allergies, especially known hypersensitivity or intolerance to lactose Known allergy to SP2086 or Valsartan or any of the excipients of the formulation of SP2086 or Valsartan</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>